ARDX — ARDELYX, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1437402 ·
Last close
$5.68
Market Cap
$1.40B
52W High
$7.43
52W Low
$5.11
ADV30
3,498,471
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 94,473,000 | 89,662,000 | -32,793,000 | -37,605,000 | 504,507,000 | 31,209,000 | 355,885,000 |
| Dec 2025 | 125,215,000 | 114,366,000 | 5,099,000 | -407,000 | 501,604,000 | 67,999,000 | 334,655,000 |
| Sep 2025 | 110,329,000 | 106,347,000 | 4,668,000 | -969,000 | 486,170,000 | 42,715,000 | 331,890,000 |
| Jun 2025 | 97,662,000 | 85,259,000 | -14,395,000 | -19,079,000 | 466,770,000 | 90,045,000 | 327,239,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,263,000
Investing CF
$-21,805,000
Financing CF
$58,469,000
CapEx
$-1,236,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-984,544,000
Inventory
$22,745,000
Receivables
$82,840,000
ST Investments
$206,865,000
EBIT TTM
$-28,890,000
Pretax Income TTM
$-57,942,000
Interest Exp TTM
$29,052,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$427,679,008
EBITDA
$-34,049,000
Free Cash Flow
$86,375
Enterprise Value
$1,400,416,128
Total Cash
$238,074,000
Total Debt
$234,128,000
Shares Out
247,029,387
Trailing EPS
$-0.24
Book Value
$0.60
ROE
-39.5%
ROA
-5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 407,320,000 | -40,977,000 | -61,599,000 | 501,604,000 | 334,655,000 | — | -42,483,000 |
| Dec 2024 | 333,615,000 | -27,950,000 | -39,136,000 | 435,754,000 | 262,465,000 | — | -44,809,000 |
| Dec 2023 | 124,456,000 | -63,276,000 | -66,067,000 | 297,579,000 | 130,763,000 | — | -89,717,000 |
| Dec 2022 | 52,158,000 | -63,759,000 | -67,207,000 | 190,066,000 | 91,737,000 | — | -70,044,000 |
TTM Snapshot
Revenues TTM
$98,241,000
NetIncome TTM
$-809,000
OpCashFlow TTM
$0
Assets (Latest)
$435,754,000
Forward EPS
$0.52
Max Pain — expiry 2026-06-18
max pain strike: $6.00 · spot: $5.67 · call oi: 15,980 · put oi: 2,099
Expected Move to 2026-06-18:
±$0.40
(7.05%) —
implied range
$5.27 –
$6.07
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GHRS | GH Research PLC | $1.40B | $20.37 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.41B | $30.30 | — |
| MLTX | MoonLake Immunotherapeutics | $1.41B | $19.19 | — |
| ATAI | AtaiBeckley Inc. | $1.41B | $3.84 | — |
| BCAX | Bicara Therapeutics Inc. | $1.42B | $21.56 | — |
News headlines (Yahoo Finance, 1h cache)
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility
2026-06-12 18:11 · Yahoo
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
2026-06-04 12:04 · Yahoo
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’
2026-06-03 23:52 · Yahoo
Should You Buy Ardelyx (ARDX)?
2026-05-30 15:18 · Yahoo
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
2026-05-19 12:01 · Yahoo
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed
2026-05-09 15:11 · Yahoo
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance
2026-05-07 15:25 · Yahoo
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
2026-05-07 12:01 · Yahoo
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report
2026-05-02 13:16 · Yahoo
Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
2026-05-01 07:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.